Boundless Bio, Inc.
BOLD evidence brief
What we can confirm
- BioSniper Score:
- 9.9 / 10
- Market Cap:
- $64.4M
What it means
What to watch
Prepared research question
What matters most for BOLD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BOLD
Boundless Bio, Inc. (BOLD) is a clinical-stage biopharmaceutical company focused on developing extrachromosomal DNA (ecDNA)-targeted therapies (ecDTx) for oncogene amplified cancers, with its lead program BBI-940 in Phase 1 trials for metastatic breast cancer.
Key risk: Cash runway limited
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$64.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Boundless Bio, Inc. (BOLD) is a clinical-stage biopharmaceutical company focused on developing extrachromosomal DNA (ecDNA)-targeted therapies (ecDTx) for oncogene amplified cancers, with its lead program BBI-940 in Phase 1 trials for metastatic breast cancer.
- Lead ecDTx BBI-940 is a novel, oral, selective degrader targeting a kinesin involved in ecDNA segregation; Phase 1 KOMODO-1 trial initiated February 2026 [sec_mda · as of 2026-03-09].
- Cash & equivalents $20.2M as of 2026-06-30; net income -$23.7M; shareholders' equity $66.0M [sec].
- Company ceased enrollment in BBI-355 (CHK1 inhibitor) and BBI-825 (ribonucleotide reductase inhibitor) trials, and wound down associated ECHO diagnostic trial [sec_mda · as of 2026-05-08].
- Spyglass platform used to identify ecDNA vulnerabilities; all ecDTx discovered internally with global rights retained [sec_mda · as of 2025-11-05].
- FDA cleared IND for BBI-940 in January 2026; nonclinical studies supported submission [sec_mda · as of 2026-03-09].
What works
- BBI-940 demonstrated potent anti-tumor activity across cancer cell lines and mouse xenograft models, including single-agent tumor regressions [sec_mda · as of 2026-03-09].
- Company retains global rights for all internally discovered ecDTx programs [sec_mda · as of 2025-11-05].
- Spyglass platform has identified multiple distinct nodes of vulnerability within ecDNA lifecycle, supporting pipeline expansion [sec_mda · as of 2026-08-07].
- FDA clearance of IND for BBI-940 in January 2026 de-risks early regulatory pathway [sec_mda · as of 2026-03-09].
What to weigh
- Cash runway limited to $20.2M as of 2026-06-30, with net loss of $23.7M in the period [sec].
- Two prior clinical programs (BBI-355, BBI-825) were discontinued, and associated diagnostic trial wound down [sec_mda · as of 2026-05-08].
- BBI-940 is still in early Phase 1; no initial proof-of-concept safety/efficacy data yet available [sec_mda · as of 2026-05-08].
- Company has no approved products and has devoted substantially all resources to R&D since 2018 [sec_mda · as of 2026-05-08].
From the filings
Quoted directly from source documents.
Lead program BBI-940 is a novel oral degrader targeting a kinesin involved in ecDNA segregation.
“Our lead ecDTx, BBI-940, is a novel, oral, selective degrader that targets a previously undrugged kinesin involved in DNA segregation, including ecDNA segregation during mitosis.”
SEC MD&A · March 9, 2026
Phase 1 trial of BBI-940 initiated in February 2026.
“In February 2026, we initiated a Phase 1, open-label, multicenter, first-in-human clinical trial of BBI-940 in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative, or ER+/HER2-, breast cancer”
SEC MD&A · March 9, 2026
Discontinuation of BBI-355 and BBI-825 trials.
“we made decisions to cease enrollment in each of these trials, and, accordingly, we also do not plan to invest further in the development of ECHO”
SEC MD&A · May 8, 2026
Catalyst timeline
- 2026-02-25 · Phase1_Start: BBI-940 KOMODO-1 trial — First-in-human Phase 1 study of BBI-940 in advanced/metastatic breast cancer initiated.
Risks & what to watch (3)›
Key risks
- Cash runway limited — Cash $20.2M as of 2026-06-30 with net loss $23.7M; may not sustain operations to proof-of-concept data [sec].
- Early-stage pipeline — Only BBI-940 in Phase 1; no approved products; prior programs discontinued [sec_mda · as of 2026-05-08].
- Clinical execution risk — BBI-940 targets novel biology (ecDNA kinesin degrader); first-in-human data pending [sec_mda · as of 2026-03-09].
What to watch
- Initial proof-of-concept safety and efficacy data from KOMODO-1 trial of BBI-940 [sec_mda · as of 2026-05-08].
- Cash runway updates and potential financing needs given $20.2M cash and ongoing net losses [sec].
- Any pipeline expansion or partnership moves leveraging Spyglass platform [sec_mda · as of 2026-08-07].
- Regulatory milestones for BBI-940 beyond Phase 1 initiation [sec_mda · as of 2026-03-09].
Sources: Catalysts · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Boundless Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Boundless Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.12 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
22 buys · 2 sells (180d)
Financials
Short Interest
as of May 20, 2026- % of float
- 1.1%
- Days to cover
- 0.4
- Shares short
- 145,151
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BOLD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Boundless Bio, Inc.?
Boundless Bio, Inc. (BOLD) is a clinical-stage biopharmaceutical company focused on developing extrachromosomal DNA (ecDNA)-targeted therapies (ecDTx) for oncogene amplified cancers, with its lead program BBI-940 in Phase 1 trials for metastatic breast cancer.
Who is the CEO of Boundless Bio, Inc.?
Mr. Zachary D. Hornby is the chief executive officer of Boundless Bio, Inc. (BOLD).
Where is Boundless Bio, Inc. headquartered?
Boundless Bio, Inc. (BOLD) is headquartered in San Diego, CA, United States.
What therapeutic areas does Boundless Bio, Inc. focus on?
Boundless Bio, Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.